Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of second patient based on encouraging...
ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia...
CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based neurostimulation company that has miniaturized neurostimulation implants for the management of...
Findings, Presented at Annual American Society of Pain & Neuroscience Conference, Demonstrate Significant and Durable Relief of Chronic Vertebrogenic Low...
Achieving the standard of care, no matter the language or disability.ANN ARBOR, MI / ACCESSWIRE / July 19, 2023 /...
Recent Pentech Health acquisition of ZOIA Pharma broadens distribution and access for patients to PKU GOLIKE®GENEVA, SWITZERLAND / ACCESSWIRE /...
George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled...
Clinical study by Cornwall NHS Trust and University of Plymouth finds anxiety, self-injurious behaviour, memory, and orientation problems are reduced...
Company adds seasoned MedTech CFO to leadership teamMARIETTA, Ga., July 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG)...
Data will be presented from an in vitro study of decellularized-flowable placental connective tissue matrix supporting cellular functions of human...
NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Data were presented to demonstrate that DPM-1003 provides a mechanism-based approach to the treatment of Rett Syndrome and is poised...
MINNEAPOLIS, June 15, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
NEW YORK, June 06, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death...
The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of...
MS Canada’s cycling fundraising event series is back this June featuring road bike tours across 12 Canadian communities, bringing people...
TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- MS Canada, the country’s leading organization in multiple sclerosis (MS) research and advocacy...
TORONTO, May 24, 2023 (GLOBE NEWSWIRE) -- On May 28, Canadians coast to coast will come together to take part...
New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates,...